Letter to the Editor

Dalfampridine is associated with de novo occurrence or reoccurrence of positive sensory symptoms in MS

Dear Editor,

Oral extended release dalfampridine (FA) is a recently approved medication that blocks voltage-dependent potassium channels inhibiting functioning of axonal membranes. It results in improved conduction affecting ambulation in a subgroup of patients with multiple sclerosis (MS) [1–2].

Paroxysmal symptoms are due to abnormal electrical discharges due to demyelinated nerve fibers and include sensory paroxysms such as painful tonic spasms. These symptoms are present in approximately 10% of subjects with MS [3]. The hypothesis is that if FA enhances sensory fiber conduction it may simultaneously incite action potential conduction in damaged sensory nerves, resulting in new positive sensory symptoms such as paraesthesia or pain.

Two retrospective reviews have reported the occurrence of new or worsened symptoms in MS patients treated with FA. In a review of 76 patients, 4 developed positive sensory symptoms (2 patients reported recurrence of TN, 1 dysesthesia and 1 bilateral leg pain), within one month of starting FA and 1 subject had a new-onset seizure. Cessation of FA was insufficient to resolve symptoms in 2 patients with recurrent TN, while subjects with de novo pain improved with therapy discontinuation [4]. In a second report of 71 subjects, 3 out of 5 subjects with a history of TN experienced recurrence of pain within 4 weeks of therapy with FA [5]. Subjects with TN showed no improvement in pain after discontinuing treatment.

We report on the occurrence of new painful symptoms in patients treated with FA prospectively, observed over 18 months. A battery of tests was performed at baseline (T0), at the end of treatment (T1) and 2 weeks later (T2). Responders had been defined by the literature as subjects with an improvement at the ΔTimed 25-foot Walk (T25FW) greater than 20%. A total of 44 patients with a mean age of 51 years (range 35–76) were included: 22 (50%) were female mean EDSS was 5.87 (range 3–7) with a mean disease duration of 14.2 years (range 3–30). Fourteen patients reported a significant improvement (> 20%) in walking speed (ΔT25FW), 3 patients were “partial responders” with a subjective improvement in walking, 22 were “non responders” and 5 subjects withdrew from the study due to adverse effects. Out of 5 subjects who reported adverse effects, 2 reported experience difficulty with balance, 2 patients experienced generalized painful paraesthesia and one exacerbation of TN. The onset of TN and generalized paraesthesia occurred within 3 days of initiating treatment with FA and pain resolved within 24–48 h of discontinuing treatment. No subjects experienced de novo TN during FA therapy.

In the current sample the frequency of painful sensory symptoms was around 7% and it represents the principal adverse effect leading to FA discontinuation. In comparison with other reports, the relationship between the onset of pain and FA treatment initiation (3 days), as well as and the rapid resolution of painful symptoms within 24–48 h from discontinuation suggests a causal relationship. Worsening of or ex novo painful symptoms presents a limitation to the use of FA.

FA should be used with caution particularly in subjects with a history of TN (approximately 2% of patients) until there is a clearer understanding of the relationship. This is important given that in some cases TN related to FA may be drug-resistant, although in our sample the subject who experienced worsening of pain related to TN recovered after FA discontinuation. A prospective study specifically assessing pain history and the occurrence of pain related to treatment would help to better understand possible predictors of de novo or reoccurring pain with the use of FA.

Author’s contributions

— Dr. Solaro: substantial contributions to conception and design; final approval of the version to be published
— Dr. Trabucco: substantial contributions to acquisition of data
— Dr. Messmer Uccelli: drafting the article and revising it critically for important intellectual content and; final approval of the version to be published

Disclosure

— Dr. Solaro served as advisory board the following companies: Biogen Idec, Merck Serono. He received speaking honoraria from Bayer Schering, Biogen Idec, Merck Serono. He received research grants and support by the FISM (Fondazione Italiana Sclerosi Multipla)
— Dr. Trabucco reports no disclosures.
— Dr. Messmer Uccelli reports no disclosures.

References

[1] A.D. Goodman, T.R. Brown, L.B. Knupp, et al., Blight AR; Fampridine MS-F203 investigators. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial, Lancet 373 (9665) (2009 Feb 28) 732–738.
[2] A.D. Goodman, T.R. Brown, K.R. Edwards, et al., Blight AR; MSF204 Investigators. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis, Ann Neurol 68 (4) (2010 Oct) 494–502.
[3] C. Solaro, M.M. Uccelli, Management of pain in multiple sclerosis: a pharmacological approach, Nat Rev Neurol 7 (9) (2011 Aug 16) 519–527.
Letter to the Editor

C. Solaro
Neurology Unit, Dept Head and Neck, ASL3 Genovese, Genova, Italy
Corresponding author at: Department of Head and Neck Neurology, ASL3 Genovese, Largo Rosso 2, 16153 Genova, Italy.
E-mail address: csolaro@libero.it.

E. Trabucco
Neurology Unit, Dept Head and Neck, ASL3 Genovese, Genova, Italy
Dept. of Experimental Medicine, Section of Diagnostic Radiology, University of Genoa, Genova, Italy

M. Messmer Uccelli
Department of Social and Health Research, AISM Italian Multiple Sclerosis Society, Genova, Italy

5 November 2015